登录查看更多内容

Restoring the Guardian of the Genome to Fight Tumors

Daniel Levine

Principal at Levine Media Group

发布日期: 2021年12月23日

The p53 protein is known as the “guardian of the genome.” It plays an essential role in suppressing tumors. Rain Therapeutics is targeting a regulator of p53 that is overexpressed in certain cancer and can inactivate it, allowing certain cancers to grow and progress. We spoke to Avanish Vellanki, chairman and CEO of Rain Therapeutics, about the company’s experimental precision therapy milademetan, how it works, and its potential to treat a range of cancers.

要查看或添加评论，请登录

Daniel Levine的更多文章

GLP-1 Agonists Beyond Obesity, A Fast and Cheap Process for Making Personalized Organoids, and AI Agents Automating Clinical Trial Operations

2025年3月2日

GLP-1 Agonists Beyond Obesity, A Fast and Cheap Process for Making Personalized Organoids, and AI Agents Automating Clinical Trial Operations

Here's what you may have missed in February from The Bio Report, RARECast, and the Life Sciences D'n'A podcasts. The…

1 条评论
The Growing Use of Digital Medicines, Empowering Patients with Data, and a New Rare Disease Drug Development Playbook

2025年2月3日

The Growing Use of Digital Medicines, Empowering Patients with Data, and a New Rare Disease Drug Development Playbook

Here's what you may have missed in January from The Bio Report, RARECast, the Life Sciences D'n'A podcasts and more…
A Biotech Review-Preview, Patients Driving Drug Development, and Generating Proteins that Nature Never Imagined

2025年1月2日

A Biotech Review-Preview, Patients Driving Drug Development, and Generating Proteins that Nature Never Imagined

The Bio Report A Very Meh-Ry Biotech Year and What’s Ahead in 2025 We continue our holiday tradition by welcoming STAT…
Targeting the Dark Genome, Preventing a Deadly Cancer, and Forging a New Field of Mitochondrial Medicine

2024年12月2日

Targeting the Dark Genome, Preventing a Deadly Cancer, and Forging a New Field of Mitochondrial Medicine

The Bio Report Preventing a Deadly Disease by Detecting It Before It Becomes Cancer Esophageal cancer is a growing…
Cell Therapies for Solid Tumors, Scaling N-of-1 Therapies, and Going Where Antibody Therapies Can't with AI

2024年11月1日

Cell Therapies for Solid Tumors, Scaling N-of-1 Therapies, and Going Where Antibody Therapies Can't with AI

The Bio Report A BET on a Novel Approach to Treat Autoimmune Conditions The BET family of proteins regulates gene…

1 条评论
Damage Control, N-of-1 Therapies, and Introducing MitoCast

2024年10月1日

Damage Control, N-of-1 Therapies, and Introducing MitoCast

The Bio Report Delivering the Goods Nearly 70 percent of patients with chronic conditions fail to take their medicines…

2 条评论
The Promise and Peril of CRISPR, Drug Developing Patients, and Going Deep with AI

2024年9月2日

The Promise and Peril of CRISPR, Drug Developing Patients, and Going Deep with AI

Here's what you may have missed in August from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. The Bio…

3 条评论
The Next Blockbuster within You, Treatments for Nonsense, and Better Decision-Making through AI

2024年8月1日

The Next Blockbuster within You, Treatments for Nonsense, and Better Decision-Making through AI

Here's what you may have missed in July from The Bio Report, RARECast, Life Sciences D'n'A podcasts. The Bio Report A…
AI, Real-World Data, and Regenerative Medicine

2024年7月1日

AI, Real-World Data, and Regenerative Medicine

Here's what you may have missed in June from The Bio Report, RARECast, Life Sciences D'n'A podcasts. The Bio Report…

1 条评论
Immunotherapies, Genetic Medicines, and Patient Advocates Reinventing Drug Development

2024年6月3日

Immunotherapies, Genetic Medicines, and Patient Advocates Reinventing Drug Development

Here's what you may have missed in May from The Bio Report, RARECast, Life Sciences D'n'A, and more. The Bio Report…

See all articles

Restoring the Guardian of the Genome to Fight Tumors

Daniel Levine

Principal at Levine Media Group

Daniel Levine的更多文章

社区洞察

其他会员也浏览了

Iruplinalkib for locally advanced or metastatic ALK+ NSCLC

Wren NETest expands to China

Building a Pipeline of Next-Generation Kinase Inhibitors

Targeting a Convergence of Signaling Pathways that Drive the Growth and Spread of Cancer

Exploiting a Vulnerability in Cancers

Programming Cell Therapies to Overcome Solid Tumor Defense Systems

Using Computational Discovery to Build Better Immunotherapies

Harnessing the Immune System to Diagnose and Treat Cancer

"Liquid biopsy epigenomic profiling for cancer subtyping"

Moffitt Investigators Discover Desmoplastic Melanoma Type Highly Responsive to Immunotherapy

Daniel Levine的更多文章

GLP-1 Agonists Beyond Obesity, A Fast and Cheap Process for Making Personalized Organoids, and AI Agents Automating Clinical Trial Operations

The Growing Use of Digital Medicines, Empowering Patients with Data, and a New Rare Disease Drug Development Playbook

A Biotech Review-Preview, Patients Driving Drug Development, and Generating Proteins that Nature Never Imagined

Targeting the Dark Genome, Preventing a Deadly Cancer, and Forging a New Field of Mitochondrial Medicine

Cell Therapies for Solid Tumors, Scaling N-of-1 Therapies, and Going Where Antibody Therapies Can't with AI

Damage Control, N-of-1 Therapies, and Introducing MitoCast

The Promise and Peril of CRISPR, Drug Developing Patients, and Going Deep with AI

The Next Blockbuster within You, Treatments for Nonsense, and Better Decision-Making through AI

AI, Real-World Data, and Regenerative Medicine

Immunotherapies, Genetic Medicines, and Patient Advocates Reinventing Drug Development

社区洞察

其他会员也浏览了

Iruplinalkib for locally advanced or metastatic ALK+ NSCLC

Wren NETest expands to China

Building a Pipeline of Next-Generation Kinase Inhibitors

Targeting a Convergence of Signaling Pathways that Drive the Growth and Spread of Cancer

Exploiting a Vulnerability in Cancers

Programming Cell Therapies to Overcome Solid Tumor Defense Systems

Using Computational Discovery to Build Better Immunotherapies

Harnessing the Immune System to Diagnose and Treat Cancer

"Liquid biopsy epigenomic profiling for cancer subtyping"

Moffitt Investigators Discover Desmoplastic Melanoma Type Highly Responsive to Immunotherapy